Cargando…

A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer

BACKGROUND: The use of stereotactic body radiotherapy (SBRT) for early-stage primary non-small cell lung cancer (NSCLC) reported excellent local control rates. But the optimal SBRT dose for oligometastatic lung tumors (OLTs) from colorectal cancer (CRC) has not yet been determined. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xin, Zamdborg, Leonid, Ye, Hong, Grills, Inga S., Yan, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180414/
https://www.ncbi.nlm.nih.gov/pubmed/30305131
http://dx.doi.org/10.1186/s12885-018-4865-9
_version_ 1783362192803889152
author Wang, Xin
Zamdborg, Leonid
Ye, Hong
Grills, Inga S.
Yan, Di
author_facet Wang, Xin
Zamdborg, Leonid
Ye, Hong
Grills, Inga S.
Yan, Di
author_sort Wang, Xin
collection PubMed
description BACKGROUND: The use of stereotactic body radiotherapy (SBRT) for early-stage primary non-small cell lung cancer (NSCLC) reported excellent local control rates. But the optimal SBRT dose for oligometastatic lung tumors (OLTs) from colorectal cancer (CRC) has not yet been determined. This study aimed to evaluate whether SBRT to a dose of 48–60 Gy in 4–5 fractions could result in similar local outcomes for OLTs from CRC as compared to early-stage NSCLC, and to examine potential dose-response relationships for OLTs from CRC. METHODS: OLTs from CRC and primary NSCLCs treated with SBRT to 48–60 Gy in 4–5 fractions at a single institution were evaluated, and a matched-pair analysis was performed. Local recurrence-free survival (LRFS) was estimated by the Kaplan-Meier method. Univariate Cox regression was performed to identify significant predictors. RESULTS: There were 72 lung lesions in 61 patients (24 OLTs from CRC in 15 patients and 48 NSCLCs in 46 patients) were analyzed with a median follow-up of 30 months. LRFS for OLTs from CRC was significantly worse than that of NSCLC when treated with 48–60 Gy/4–5 fx (p = 0.006). The 1, 3 and 5-year LRFS of OLTs from CRC vs NSCLC were 80.6% vs. 100%, 68.6% vs. 97.2%, and 68.6% vs. 81.0%, respectively. On univariate analysis, OLTs from CRC treated with higher dose (BED(10) = 132 Gy) exhibited significantly better local recurrence-free survival than those treated to lower doses (BED(10) ≤ 105.6 Gy) (p = 0.0022). The 1 and 3-year LRFS rates for OLTs treated to a higher dose (BED(10) = 132 Gy) were 88.9% and 81.5%, vs 33.3%, and not achieved for lower doses (BED(10) ≤ 105.6 Gy). CONCLUSION: The LRFS of OLTs from CRC after SBRT of 48–60 Gy/4–5 fx was significantly worse than that of primary NSCLC. Lower dose SBRT appeared to have inferior control for OLTs of CRC in this cohort. Further studies with larger sample sizes are needed.
format Online
Article
Text
id pubmed-6180414
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61804142018-10-18 A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer Wang, Xin Zamdborg, Leonid Ye, Hong Grills, Inga S. Yan, Di BMC Cancer Research Article BACKGROUND: The use of stereotactic body radiotherapy (SBRT) for early-stage primary non-small cell lung cancer (NSCLC) reported excellent local control rates. But the optimal SBRT dose for oligometastatic lung tumors (OLTs) from colorectal cancer (CRC) has not yet been determined. This study aimed to evaluate whether SBRT to a dose of 48–60 Gy in 4–5 fractions could result in similar local outcomes for OLTs from CRC as compared to early-stage NSCLC, and to examine potential dose-response relationships for OLTs from CRC. METHODS: OLTs from CRC and primary NSCLCs treated with SBRT to 48–60 Gy in 4–5 fractions at a single institution were evaluated, and a matched-pair analysis was performed. Local recurrence-free survival (LRFS) was estimated by the Kaplan-Meier method. Univariate Cox regression was performed to identify significant predictors. RESULTS: There were 72 lung lesions in 61 patients (24 OLTs from CRC in 15 patients and 48 NSCLCs in 46 patients) were analyzed with a median follow-up of 30 months. LRFS for OLTs from CRC was significantly worse than that of NSCLC when treated with 48–60 Gy/4–5 fx (p = 0.006). The 1, 3 and 5-year LRFS of OLTs from CRC vs NSCLC were 80.6% vs. 100%, 68.6% vs. 97.2%, and 68.6% vs. 81.0%, respectively. On univariate analysis, OLTs from CRC treated with higher dose (BED(10) = 132 Gy) exhibited significantly better local recurrence-free survival than those treated to lower doses (BED(10) ≤ 105.6 Gy) (p = 0.0022). The 1 and 3-year LRFS rates for OLTs treated to a higher dose (BED(10) = 132 Gy) were 88.9% and 81.5%, vs 33.3%, and not achieved for lower doses (BED(10) ≤ 105.6 Gy). CONCLUSION: The LRFS of OLTs from CRC after SBRT of 48–60 Gy/4–5 fx was significantly worse than that of primary NSCLC. Lower dose SBRT appeared to have inferior control for OLTs of CRC in this cohort. Further studies with larger sample sizes are needed. BioMed Central 2018-10-10 /pmc/articles/PMC6180414/ /pubmed/30305131 http://dx.doi.org/10.1186/s12885-018-4865-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wang, Xin
Zamdborg, Leonid
Ye, Hong
Grills, Inga S.
Yan, Di
A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer
title A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer
title_full A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer
title_fullStr A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer
title_full_unstemmed A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer
title_short A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer
title_sort matched-pair analysis of stereotactic body radiotherapy (sbrt) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180414/
https://www.ncbi.nlm.nih.gov/pubmed/30305131
http://dx.doi.org/10.1186/s12885-018-4865-9
work_keys_str_mv AT wangxin amatchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer
AT zamdborgleonid amatchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer
AT yehong amatchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer
AT grillsingas amatchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer
AT yandi amatchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer
AT wangxin matchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer
AT zamdborgleonid matchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer
AT yehong matchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer
AT grillsingas matchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer
AT yandi matchedpairanalysisofstereotacticbodyradiotherapysbrtforoligometastaticlungtumorsfromcolorectalcancerversusearlystagenonsmallcelllungcancer